Starpharma (SPHRY) announced the signing of a collaboration and license agreement with Genentech, a member of the Roche Group (RHHBY), to develop potential cancer therapies that leverage Starpharma’s proprietary DEP drug delivery technology. Starpharma will receive an upfront payment of $5.5M, and is eligible for development, commercial, and net sales milestones of up to $564M. In addition to this amount, Starpharma is eligible for tiered royalties on global net sales of products resulting from the collaboration. Starpharma will employ its proprietary DEP platform technology to develop dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets. Starpharma has granted Genentech an exclusive worldwide license under Starpharma’s IP to develop and commercialize products resulting from the collaboration, which could include multiple products for each target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Genentech announces evERA study meets both co-primary endpoints
- Nvidia to invest $5B in Intel, ABC pulls ‘Jimmy Kimmel Live!’: Morning Buzz
- Roche achieves CLIA ‘Moderate Complexity’ categorization for Ionify assay
- Video: Intel powered up by Nvidia investment
- Roche enters into definitive merger agreement to acquire 89bio